This 2020 Biotech IPO Is Poised to Break Out in 2021

1 min read

The notoriously difficult-to-target RAS cancer mutations may soon have a new enemy, and 230,000 U.S. cancer patients with RAS mutations may soon have good news. Revolution Medicines (NASDAQ: RVMD) and its lead compound, RMC-4630, are looking to become the backbone of treatment for RAS-driven cancers — an opportunity worth more than $20 billion in the U.S. alone.

Currently in phase 2 trials, RMC-4630 is an oral therapy that Revolution’s management team believes can be used either as a monotherapy or in combination treatment for cancer patients with tumors containing RAS mutations. In early trials, RMC-4630 has shown anti-tumor activity across multiple solid tumors, and there are multiple clinical readouts coming in the next year that may push Revolution Medicines even further past the 55%-plus gains investors have enjoyed since the company’s February 2020 IPO.

Image source: Getty Images.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Dave & Buster’s Entertainment Inc (PLAY) Q4 2020 Earnings Call Transcript

Next Story

Thinking About Buying AMC and GameStop? These 2 Robinhood Stocks Are Much Better Picks

Latest from Blog